PNNL researchers developed a new computational workflow to study day-to-night gene expression dynamics of cyanobacterium in real time.

Understanding molecular modifications of proteins in the red yeast could help scientists re-engineer the organism’s phenotype.

Continued studies will deepen scientists’ understanding of virus-host interactions at the molecular level and also pave the way for developing better drugs to fight emerging viruses.

Flexible, high-throughput proteomics approach identifies protein modifications related to pancreatic stress and insulin production.

Scientists uncover how cyanobacteria's circadian cycle controls carbon and energy metabolism, increasing carbon dioxide-to-bioproducts yields.

Scientists map how transitions from day to night control gene regulatory networks in cyanobacteria, revealing key orchestrators of metabolic switching.

PNNL scientists use proteomics to unveil how high-density lipoproteins protect against cholesterol accumulation in the artery wall.

A cross-institutional team of scientists developed PeakQC, a new software tool for automated quality control of mass spectrometry data.

Despite the widespread presence of RNA viruses in soils, little is known about the relative contributions and interactions of biological and environmental factors shaping the composition of soil RNA viral communities.

Data reveals mechanisms in our bodies that can help us fight viral pathogenesis.

The new PTM-Psi workflow opens the door for uncovering molecular insights within proteomics datasets.

Scientists developed a process (or pipeline) that combined molecular probes—a specific chemical that binds to microbes carrying out a particular function—with a method that isolated these cells from their complex community.

Scientists screen for nanobodies that recognize wild type and mutant functional proteins to develop a framework to disrupt protein interactions that can cause disease.

Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.